ENVALITH

FRONTEO, Inc. 2Q Earnings Flash

Life Science AI revenue rose 40%. The focus now shifts to a recovery in Risk Management and progress toward 2H profitability.

PublishedNovember 16, 2026 at 23:00 GMT+9

Key Positives From The 2Q Results

Life Science AI revenue grew to JPY 384M (+40.3% YoY), and the segment narrowed its operating loss despite adding research headcount. On a standalone basis, the consolidated 2Q operating loss narrowed to approx. -JPY 65M from -JPY 179M in 1Q (our estimate). This suggests the cost-structure reforms are starting to take effect.

  • AI Drug Discovery
    : Revenue of JPY 257M (+38.3%). Co-creation projects and DDAIF Innovation Bridge engagements continue to accumulate, building a base of stable revenue.
  • New and Repeat Wins
    : A new co-creation project was launched with Astellas Pharma, and Santen Pharmaceutical awarded a second project. The company is winning both new clients and repeat orders.
  • Innovation Bridge Expansion
    : Portfolio companies supported rose to seven as of end-September, with two moving to the second phase. The NB Health Laboratory program targets out-licensing as early as FY2026.
  • DX Segment
    : Operating income of JPY 68M (+48.8%). Revenue growth at Alnetz is supporting consolidated revenue.
  • SG&A Reduction
    : 2Q standalone SG&A was approx. JPY 674M, down from JPY 810M in 1Q (our estimate). Portfolio restructuring, including the sale of the Korean subsidiary, is progressing.

Key Concerns From The 2Q Results

Risk Management revenue fell 24.2%, and the segment swung from operating income of JPY 137M to an operating loss of -JPY 114M. Large-client cancellations in Compliance Support are weighing on results, and rebuilding the recurring-revenue base is the key challenge. On the balance sheet, cash is declining as investment runs ahead of returns, while interest expense is rising.

  • Compliance Support
    : Revenue -33.7%. Cancellations by large clients, including manufacturers, outweighed contributions from new engagements with major financial institutions.
  • Gross Margin Compression
    : Gross Profit Margin fell 9.9pt. We attribute this to lower revenue in the high-margin Risk Management segment combined with a rising mix of DX revenue.
  • Negative FCF
    : Operating CF of -JPY 135M and investing CF of -JPY 482M yielded FCF of -JPY 618M (our estimate). Spending on intangible assets and equity investments in drug discovery companies ran ahead of returns.
  • Rising Interest Burden
    : Interest expense rose 81.8% to JPY 37M. Greater reliance on borrowings is beginning to weigh on non-operating results.
  • AI Medical Devices
    : Revenue growth includes one-off income related to medical device development, so its sustainability needs to be assessed.

Focus Areas / Items To Monitor Going Forward

  • 2H Profit Hurdle
    : Achieving the full-year operating income plan of JPY 300M requires JPY 544M in 2H (our estimate). Versus approx. JPY 746M in 2H of the prior year, the key question is how far the company can offset declining Risk Management revenue.
  • Compliance and Economic Security
    : We want to see how far contributions from major financial institution engagements build in Compliance Support. We will also watch whether government projects in Economic Security are booked in 2H as planned.
  • Pipeline Out-Licensing
    : We will track out-licensing timing and deal terms for the pipeline, including the NB Health Laboratory program. Whether AI Drug Discovery can transition to non-linear, milestone-based revenue will drive mid- to long-term value.
Discussion Points For Management
  • The bottom-up basis by business area for 2H operating income of JPY 544M, and the probability of winning government contracts
  • The reasons behind cancellations in Compliance Support, and measures to restore retention among existing clients
  • The status of out-licensing negotiations for the NB Health Laboratory program, and the timing of revenue recognition
  • A breakdown of the gross margin decline, separating segment mix shifts from research headcount costs booked in COGS
  • The funding plan for balancing reliance on short-term borrowings with a growing investment securities portfolio

Key Financial Highlights

ItemValueYoY
RevenueJPY 3,292M-2.5%
Cost of Goods SoldJPY 2,052M+16.1%
Gross ProfitJPY 1,239M-22.8%
└Gross Profit Margin37.7%-9.9pt
SG&AJPY 1,484M-8.1%
Operating Income-JPY 244MPrior Year -JPY 7M
Recurring Profit-JPY 229MPrior Year -JPY 25M
Extraordinary IncomeJPY 66M+15.8%
└Gain on Sale of Shares of AffiliatesJPY 47MPrior Year -
Extraordinary LossesJPY 71M+32.2%
└Restructuring CostsJPY 56MPrior Year -
Interim Net Income Attributable to Owners of Parent Company-JPY 186MPrior Year -JPY 72M
EPS-JPY 4.77Prior Year -JPY 1.85
Comprehensive Income-JPY 193MPrior Year JPY 273M
  • Margin Squeeze
    : Revenue was roughly flat YoY, but COGS rose 16.1%, cutting Gross Profit by JPY 367M. The JPY 130M reduction in SG&A could not offset this, so the operating loss widened.
  • 2Q Standalone
    : Revenue was approx. JPY 1,660M, +1.7% QoQ (our estimate).
  • Extraordinary Income
    : Includes the gain on the sale of the Korean subsidiary FRONTEO Korea and a JPY 13M reversal of foreign currency translation adjustments.
  • Restated Prior-Year Figures
    : Prior-year figures reflect the finalization of provisional accounting for the Alnetz business combination.

Performance By Business Segment

Life Science AI and DX both grew revenue. However, the revenue decline and swing to a loss in Risk Management had a larger impact, widening the consolidated operating loss. From this fiscal year, the Business Intelligence Professional Support area moved from the DX segment to Risk Management, and prior-year figures have been restated for comparison.

Segment Performance Table

SegmentRevenueYoYOperating IncomeYoYMargin
Life Science AIJPY 384M+40.3%-JPY 149MLoss Narrowed (Prior Year -JPY 184M)-38.9%
Risk ManagementJPY 1,539M-24.2%-JPY 114MSwung From Profit to Loss (Prior Year JPY 137M)-7.4%
DXJPY 1,429M+32.7%JPY 68M+48.8%4.8%
Adjustments-JPY 60M--JPY 49M--
ConsolidatedJPY 3,292M-2.5%-JPY 244MLoss Widened (Prior Year -JPY 7M)-7.4%

(Segment revenue includes inter-segment sales.)

Strong Performers
  • AI Drug Discovery: Revenue of JPY 257M (+38.3%). New clients and repeat orders built up in co-creation projects, and biotech venture support added new contracts with SCOHIA PHARMA and others.
  • AI Medical Devices: Revenue of JPY 127M (+44.6%). Results include "Talk Lab KIBIT," launched in September 2025, plus one-off income related to medical device development.
  • DX (Alnetz): Revenue from external customers of JPY 1,368M (+27.9%). The segment captured demand for in-house DX enablement and system development, with higher revenue driving profit growth.
Underperformers
  • Business Intelligence – Compliance Support: Revenue of JPY 403M (-33.7%). Engagements with major financial institutions began contributing, but cancellations by large clients, including manufacturers, weighed on results.
  • Legal Tech AI: Revenue of JPY 904M (-17.2%). Fewer e-discovery matters were partly offset by digital forensics work driven by investigative demand from third-party committees and similar bodies.
  • Economic Security: Revenue of JPY 139M (-40.6%). Private-sector cancellations hurt results, and government projects are planned to be booked mainly in 2H.
  • Business Intelligence – Professional Support: Revenue of JPY 91M (-4.1%). Winning new engagements is taking longer than expected.

Progress Rate Versus Full-Year Guidance

Revenue progress stands at 43.3%, in line with 44.2% a year earlier (our estimate). Operating income, however, is in the red, so reaching the full-year plan of JPY 300M requires JPY 544M in 2H alone (our estimate). That is below the prior-year 2H result. The key to delivering the plan is how far the company can reverse the downtrend in Risk Management revenue during 2H.

ItemValue (2Q Cumulative)Full-Year ForecastProgress
RevenueJPY 3,292MJPY 7,600M43.3%
Operating Income-JPY 244MJPY 300M-
Recurring Profit-JPY 229MJPY 250M-
Net Income Attributable to Owners of Parent Company-JPY 186MJPY 150M-

Changes To Guidance

Full-year guidance announced on May 15, 2026 (Revenue JPY 7,600M, Operating Income JPY 300M, Net Income JPY 150M) is unchanged. The company expects earnings to build through 2H and plans to return to profitability for the full year.

Commentary On Shareholder Returns

The interim dividend is JPY 0.00, and the year-end dividend forecast remains unchanged at JPY 0.00. No share buybacks were conducted during the interim period.

Financial Position

The Equity Ratio held at 39.5%, in line with the prior fiscal year-end. However, leverage is rising as cash declines and borrowings increase. The company now faces the challenge of balancing investment in AI drug discovery with financial stability.

  • Key Figures
  • Leverage Metrics
ItemValueAdditional Information
Cash and Cash EquivalentsJPY 1,257M-27.1% vs. prior FY-end
Shareholders' EquityJPY 3,463M-5.3% vs. prior FY-end
Interest-Bearing DebtJPY 4,180M+3.9% vs. prior FY-end; includes lease obligations of JPY 22M
└Short-Term BorrowingsJPY 2,720M+4.6% vs. prior FY-end
└Current Portion of Long-Term BorrowingsJPY 408M-7.4% vs. prior FY-end
└Long-Term BorrowingsJPY 1,029M+7.5% vs. prior FY-end
Accounts Receivable and Contract AssetsJPY 1,081M-28.2% vs. prior FY-end
Investment SecuritiesJPY 2,404M+14.9% vs. prior FY-end; reflects equity investments in drug discovery companies and fair value changes
GoodwillJPY 1,002MRelated to the Alnetz acquisition
EBITDAJPY 16MOperating Income + depreciation of JPY 224M + goodwill amortization of JPY 36M, our estimate; prior year JPY 196M

Disclosures Released Alongside The Earnings Announcement

None

Major Announcements During The Quarter

  • 2026/08/20
    Began providing "KIBIT Knowledge Probe" to The 77 Bank. The tool upgrades audits of customer interaction records for financial product sales and extends adoption among regional banks.
  • 2026/09/03
    Launched joint research with Chiome Bioscience on bispecific antibody drugs. The partnership combines DDAIF-driven target discovery with antibody drug discovery technology, expanding the in-house research pipeline.
  • 2026/10/27
    Launched a co-creation project with Otsuka Pharmaceutical on drug discovery target exploration in the renal field. This adds another co-creation engagement with a major pharma company and should contribute to 2H revenue.
  • 2026/10/29
    Launched a second co-creation project with Maruho in dermatology. The repeat order from an existing client shows the recurring-engagement revenue model is taking hold.
  • 2026/11/02
    Developed two new technologies, including "Auto Due Diligence" for automating supply chain investigations, and filed patent applications. The move strengthens competitiveness in Economic Security.

Large-Shareholding Filings / Material Proposals Over The Past Year

  • Masahiro Morimoto: 10.3%→16.2% (2026/03/16) - Held as a stable shareholder in his capacity as founder and Representative Director of the issuer (amended report)
  • Capstan Medical: 7.0%→5.9% (2026/02/20) - Pure investment via MORIMOTO Investment Limited Partnership No. 1
  • Capstan Medical: 5.9%→0.0% (2026/03/16) - Shareholding ratio decreased by 1% or more
Disclaimer

ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.

  • Purpose and Disclaimer Regarding Investment Decisions

    This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.

  • Information Sources, Accuracy, and Disclaimer of Warranty

    This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.

  • Limitation of Liability

    ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.

  • Potential Conflicts of Interest

    ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.

  • No Obligation to Change or Update Content

    The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.

  • Governing Language

    This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.

  • Copyright

    All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.

  • Use for Other Investment Products

    Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.